Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.56 |
| ▸ | PGR | P06401 | 1/20 | 0.53 |
| ▸ | RORA | P35398 | 1/20 | 0.53 |
| ▸ | RORC | P51449 | 1/20 | 0.53 |
| ▸ | RORB | Q92753 | 1/20 | 0.53 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8862370 | 1.00 | CNR2 (0.56) | CNR2PGRRORARORCRORB | |
| SCHEMBL25318908 | 1.00 | CNR2 (0.56) | CNR2PGRRORARORCRORB | |
| SCHEMBL28002722 | 1.00 | CNR2 (0.56) | CNR2PGRRORARORCRORB | |
| SCHEMBL30484777 | 1.00 | CNR2 (0.56) | CNR2PGRRORARORCRORB | |
| SCHEMBL30484776 | 1.00 | CNR2 (0.56) | CNR2PGRRORARORCRORB | |
| SCHEMBL6421284 | 0.98 | CNR2 (0.57) | CNR2PGRRORARORCRORB | |
| SCHEMBL8129987 | 0.92 | CNR2 (0.50) | CNR2PGRRORARORCRORB | |
| SCHEMBL11137168 | 0.87 | FABP4 (0.59) | CNR2KDM4ETDP1HTTALDH1A1 | |
| SCHEMBL6910089 | 0.87 | PGR (0.56) | CNR2PGRRORARORCRORB | |
| SCHEMBL11137775 | 0.86 | FABP4 (0.57) | CNR2KDM4EMAPTHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4466253-A1 | MODULATORS OF SK4 POTASSIUM CHANNEL AND USES THEREOF | Ramot at Tel-Aviv University Ltd. (IL) | 2024-11-27 | — | — | EP | disclosed |
| US-20240366571-A1 | MODULATORS OF SK4 POTASSIUM CHANNEL AND USES THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2024-11-07 | — | — | US | disclosed |
| WO-2023135603-A1 | MODULATORS OF SK4 POTASSIUM CHANNEL AND USES THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2023-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366571-A1 | MODULATORS OF SK4 POTASSIUM CHANNEL AND USES THEREOF | KCNMB4, KCNN4, KCNN3 | CNR2 1261/4885PGR 3584/4885RORA 4497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.